Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Stock-Based Compensation Awards Granted

The consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows:

	Year Ended
	December 31,
	2020		2019
General and administrative expenses	$	1,582	$	1,163
Research and development expenses		462		408
Total	$	2,044	$	1,571

Schedule of Stock-Based Compensation Expense Classified in Research and Development Expenses

	Year Ended
	December 31,
	2020		2019
Lucid Diagnostics Inc 2018 Equity Plan – research and development expenses	$	52	$	158
PAVmed Inc 2014 Equity Plan - research and development expenses		13		16
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc	$	65	$	174

Schedule of Unrecognized Compensation Expense

As of December 31, 2020, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, as discussed above, is as follows:

	Unrecognized Expense		Weighted Average Remaining Service Period
PAVmed Inc. 2014 Equity Plan
Stock Options	$	1,866		0.9 years
Restricted Stock Awards	$	1,796		2.1 years
Lucid Diagnostics Inc. 2018 Equity Plan
Stock Options	$	49		0.8 years

2014 Equity Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Summarizes Information About Stock Options

Stock options issued and outstanding under the PAVmed Inc. 2014 Equity Plan are as follows:

	Number Stock Options			Weighted Average Exercise Price		Remaining Contractual Term (Years)		Intrinsic Value(2)
Outstanding stock options at December 31, 2018		3,327,140		$	3.68		8.3
Granted(1)		1,925,000		$	1.00
Exercised		—		$	—
Forfeited		(48,611	)	$	5.00
Outstanding stock options at December 31, 2019		5,203,529			2.58		8.1	$	394
Vested and exercisable stock options at December 31, 2019		3,270,487		$	3.45		7.5	$	126
Outstanding stock options at December 31, 2019		5,203,529		$	2.58
Granted(1)		1,595,000		$	2.13
Exercised		—		$	—
Forfeited		—		$	—
Outstanding stock options at December 31, 2020		6,798,529		$	2.55		7.3	$	2,558
Vested and exercisable stock options at December 31, 2020		4,861,433		$	2.88		6.7	$	1,707

(1)	Stock options granted under the PAVmed Inc. 2014 Equity Plan vest ratably over twelve quarters generally commencing with the grant date quarter and have a ten year contractual term from date-of-grant.
(2)	The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of December 31, 2020 and 2019 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price.

Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions

The stock options granted under the PAVmed Inc. 2014 Equity Plan during the years ended December 31, 2020 and 2019, had a weighted average estimated fair value of $1.27 per share and $0.48 per share, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions:

	Year Ended December 31,
	2020			2019
Expected term of stock options (in years)		5.8			5.7
Expected stock price volatility		73	%		50	%
Risk free interest rate		0.5	%		2.4	%
Expected dividend yield		0	%		0	%

2018 Equity Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Summarizes Information About Stock Options

Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan for the period noted is as follows:

	Number Stock Options			Weighted Average Exercise Price		Remaining Contractual Term (Years)
Outstanding stock options at December 31, 2018		375,000		$	0.60		9.4
Granted		620,000		$	1.02
Exercised		—		$	—
Forfeited		—		$	—
Outstanding stock options at December 31, 2019		995,000		$	0.86		9.0
Granted		—		$	—
Exercised		(3,333	)	$	1.50
Forfeited		—		$	—
Outstanding stock options at December 31, 2020		991,667		$	0.86		8.0
Vested and exercisable stock options at December 31, 2020		772,491		$	0.83		7.9

⁽¹⁾ Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan, have a ten-year contractual term from date of grant, and vest ratably over twelve successive calendar quarters, with first vesting date in the quarter of the date of grant.

Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions

As noted above, in the year ended December 31, 2020, there were no stock-based awards granted under the Lucid Diagnostics Inc 2018 Equity Plan. In the previous year ended December 31, 2019, stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.32 per share, and was calculated using the following weighted average Black-Scholes valuation model assumptions:

Expected term of stock options (in years)	5.8
Expected stock price volatility	63	%
Risk free interest rate	2.1	%
Expected dividend yield	0	%